23 /100
LOW RISK
Score updated May 29, 2026

DNLI — Denali Therapeutics Inc. Dilution Risk Tracker

Track DNLI dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DNLI — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
0
📊 Float Risk
2
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for DNLI.
🔔 Track DNLI — Get forecast alerts →

💹 Market Data

Market Cap$3.32B
Shares Outstanding158.71M
Float144.27M
Cash$987.68M
Debt$40.05M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 11.5% shares (2025Q4 vs prior)
253 institutional holders · 155.04M shares
#1 VANGUARD GROUP INC 13.06M shares
#2 BlackRock, Inc. 12.72M shares
#3 BAILLIE GIFFORD & CO 12.31M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest14.81M
Days to Cover9.9
% of Float10.3%
FINRA data as of Apr 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2017
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track DNLI Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DNLI — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for DNLI
📊 DNLI FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 DNLI Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.